EVOTEC SE INH O.N.
Commented by Matthias Schomber on June 16th, 2026 | 07:20 CEST
Vonovia is Struggling, Evotec is Reinventing Itself, and dynaCERT is Expanding—Three Stocks Under the Microscope! Who has the Upper Hand?
Three stocks, three completely different stories, yet all three are currently at a point that is likely to determine their performance over the coming months. Vonovia, for example, is struggling with rising interest rates and a real estate market that refuses to recover. Evotec is in the midst of a profound restructuring and has just reshuffled its supervisory board. And dynaCERT, the Canadian cleantech specialist, is pushing ahead in Southeast Asia: Vietnam could be the next step. On top of that, a geopolitical shock is shaking up markets: the US and Iran have reportedly reached a deal, and the Strait of Hormuz is set to reopen. Oil prices have fallen sharply in response. What this means for energy costs, real estate markets, and cleantech companies is still unclear. But a closer look reveals that all three stocks offer more than just headlines. Where should investors enter now?
Read
Commented by Armin Schulz on June 12th, 2026 | 06:40 CEST
The Biotech and Life Sciences Boom: Evotec, BioNxt Solutions, and Merck – Which Is Worth Investing In?
The life sciences and pharmaceutical industry is undergoing a structural transformation. Value creation is no longer driven by individual blockbuster drugs, but rather by platform technologies, patent portfolios, and strategic deals. This new capital market logic rewards companies with protectable intellectual property and smart licensing agreements—not just pure pipeline developers. For private investors, this creates high-yield niches with reduced regulatory risks. The key question remains: who controls the levers in the innovation ecosystem? Those who recognize this structure early can benefit disproportionately. Today we focus on Evotec, BioNxt Solutions, and Merck.
Read
Commented by André Will-Laudien on May 20th, 2026 | 08:05 CEST
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus!
In recent months, the stock market has focused primarily on high-tech and defence stocks. While this strategy may have worked well for investors in the short term, it has also pushed several life sciences stocks to levels that some consider overly depressed. The Hamburg-based drug discovery company Evotec has lost around 75% of its market value over the past three years, with similar declines seen at BioNTech, Formycon, and BioNxt Solutions. Yet some pipelines are indeed valuable and backed by years of research. For a buyer with deep pockets, this could represent an attractive opportunity, as much of the costly early-stage work has already been completed. We are looking at a sector that has been unjustly forgotten. Where do opportunities lie for risk-conscious investors?
Read
Commented by Fabian Lorenz on May 19th, 2026 | 07:25 CEST
BUY RECOMMENDATIONS for RENK and Desert Gold! SHOCK for Evotec!
While gold prices are weakening, Desert Gold shares are in a clear uptrend. And if analysts are to be believed, a tenfold increase is possible. Desert Gold is set to become a gold producer in just a few months and generate strong cash flows. And it does not matter whether gold is trading at USD 4,000 or USD 6,000 per ounce. RENK stock has been upgraded to "Buy." Not because the future outlook has improved, but because the price has plummeted. This means the valuation now offers upside potential again. The growth prospects are quite positive. Meanwhile, analysts have recently noted a lack of growth prospects at Evotec. For many, "Project Horizon" focuses too heavily on cost reduction. But growth is precisely what is expected from a biotech company. And now, the restructuring costs are also to be financed through a convertible bond.
Read
Commented by Fabian Lorenz on May 12th, 2026 | 07:10 CEST
SHARE PRICE DROP for Nel ASA and Evotec! SHARE PRICE OPPORTUNITY for HPQ Silicon!
Is HPQ Silicon's stock poised for a revaluation? There are certainly good reasons to think so. Its high-performance batteries have once again impressed. This could signal a significant technological leap forward for applications in drones, defence, mobility, and high-end electronics. Nel ASA's new generation of pressure-driven alkaline electrolyzers is expected to represent such a technological leap. On the stock market, however, the announcement triggered a sell-off. Investors had likely speculated on bigger news following the rally. There is disappointment also at Evotec. The management board provided an optimistic outlook in its Q1 results, but first-quarter revenue and EBITDA were initially underwhelming. Analysts' price targets vary widely.
Read
Commented by Carsten Mainitz on May 8th, 2026 | 07:25 CEST
Take note! The stock market is (still) ignoring key developments at Desert Gold, Evotec, and Mutares!
The past few weeks have been challenging for stock market traders. However, investors should not dwell too long on missed opportunities; they still exist across a wide range of industries and for various reasons. Desert Gold, Evotec, and Mutares currently stand out. These companies have one thing in common: their groundbreaking progress has so far been ignored by the stock market and is only partially reflected in their prices. This opens up lucrative opportunities for forward-thinking investors. Analysts see significant upside potential for all three stocks. Who is leading the race?
Read
Commented by André Will-Laudien on May 7th, 2026 | 08:25 CEST
Moving Ahead with Strong Concepts and Easing Tensions in the Middle East! MustGrow, K+S, Evotec, and Novo Nordisk in Focus
Created and published on behalf of MustGrow Biologics Corp.
What a headline: An agreement between the US and Iran – markets up 2% in just one minute! It can happen that fast. For investors, this is welcome news, as a de-escalation in the Iran conflict would significantly ease global supply chains and reduce pressure on critical transport routes. In particular, the Strait of Hormuz would lose some of its significance as a geopolitical risk factor, potentially stabilizing global flows of goods and energy. Easing tensions are also likely to lower transport costs again, shorten delivery times, and dampen price volatility. For companies in the food, healthcare, and agricultural technology sectors, this creates greater planning certainty and new growth opportunities. MustGrow Biologics and K+S could benefit from more stable agricultural markets, while Evotec and Novo Nordisk may gain additional tailwinds in a calmer healthcare environment. Investors are increasingly turning to stocks that promise sustainable growth and reliable returns in a more stable market setting. The key question now: will volatility finally decline as well?
Read
Commented by Fabian Lorenz on May 5th, 2026 | 07:40 CEST
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000?
Evotec's share price has skyrocketed. Following positive news from a drug discovery partnership, the stock temporarily climbed by over 9%. This continues the upward trend of recent weeks. Is there perhaps even more to come? An interesting candidate for a summer rally is Desert Gold. The company plans to begin gold production for the first time next month. Additionally, the resource is set to be expanded through a drilling program. Analysts see potential for a tenfold increase. Analysts are also optimistic about Rheinmetall. They even see the defence stock rising back above EUR 2,000. However, the sector currently lacks momentum. Most recently, the DAX-listed company reported on a milestone.
Read
Commented by Armin Schulz on April 30th, 2026 | 07:00 CEST
Weight-Loss Injections, Cancer Cell Inhibitors & the Power of Algorithms: Adding Potential to Your Portfolio with Novo Nordisk, Vidac Pharma, and Evotec
The healthcare market faces a paradoxical scenario in 2026. Public health funds are groaning under record spending, while groundbreaking technologies are redefining medicine. AI-driven drug discovery and personalized therapies promise efficiency gains, but regulatory hurdles and price wars are causing stock prices to fluctuate. In this complex landscape, the wheat is being separated from the chaff. Three distinct biotech strategies could now provide the decisive edge. Novo Nordisk dominates the mass market for metabolic diseases, Vidac Pharma is tackling cancer in novel ways, and Evotec is digitizing the entire drug discovery process.
Read
Commented by André Will-Laudien on April 21st, 2026 | 06:55 CEST
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight
The Middle East conflict is once again bringing global supply chains into focus and increasing pressure on vulnerable supply routes. The Strait of Hormuz, in particular, remains a key geopolitical risk factor because it is of great importance for the global flow of goods and energy. If tensions arise there, transportation costs, delivery times, and price fluctuations can quickly escalate. This creates new opportunities as well as risks, particularly for companies involved in food, health, and agricultural technology. MustGrow and K+S ensure the global food supply through fertilizers, while Evotec and BioNTech operate in the complex landscape of health-related issues. Despite uncertain conditions, dynamic investors are keeping an eye on the stocks that deliver comparatively robust results in a volatile market environment. We dig a little deeper!
Read